News | October 02, 2024
Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The inspection conducted by EDQM at its Visakhapatnam facility
The observations are of procedural in nature and will be responded to within the stipulated time
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
The net-zero target approval complements the company's near-term emission reduction targets
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Subscribe To Our Newsletter & Stay Updated
